News

lupus.bmj9d
LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients ...
Background Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, approved in multiple countries for the treatment of adults with plaque psoriasis.¹ ² ...
Nature19d
The Selective Class III/V Receptor Tyrosine Kinase Inhibitor SU11657 Inhibits Tumor Growth and Angiogenesis in Experimental Neuroblastomas Grown in Mice
SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors (PDGFR), VEGF receptors (VEGFR), stem cell ...
Frontiers26d
The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors
Additionally, ongoing clinical trials of Bruton’s tyrosine kinase (BTK) inhibitors were identified through ... complement receptor 3; IGF-1, insulin-like growth factor 1; IL, interleukin; OPC, ...
C&EN27d
Discovery of Imidazo[1,2-b]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitors
Collaborative Innovation Centre of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Henan Engineering Research ...
The EMBO Journal29d
Bacterial effectors mediate kinase reprogramming through mimicry of conserved eukaryotic motifs
whereby the canonical serine/threonine host kinase GSK3 gains tyrosine-directed activity towards neosubstrates, promoting Salmonella virulence. Yet, both the mechanism behind the switch in GSK3’s ...